Targets › GCNT1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
Glycosyltransferase that catalyzes the transfer of an N-acetylglucosamine (GlcNAc) moiety in beta1-6 linkage from UDP-GlcNAc onto mucin-type core 1 O-glycan to form the branched mucin-type core 2 O-glycan. The catalysis is metal ion-independent and occurs with inversion of the anomeric configuration of sugar donor (By similarity). (UniProt, Q02742)
Open in Phaseline: the race on GCNT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Margaret Gatti-Mays | Naxitamab Humanized anti-GD2 monoclonal antibody | GCNT1 | Phase 1 | Anatomic Stage IV Breast Cancer AJCC v8 | Oct 2027 |
Anatomic Stage IV Breast Cancer AJCC v8 (1)
mixed (1)
Margaret Gatti-Mays (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.